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Facilitating Regulatory Approval of 
Multipurpose Prevention Technologies for  
Sexual and Reproductive Health
The Need
Multipurpose prevention technologies (MPTs) that 
address women’s sexual and reproductive health (SRH) 
needs—through preventing unintended pregnancies and/
or sexually transmitted infections (STIs), including HIV—
could make a major contribution to global health. Unsafe 
sex is an enormous public health problem for women, 
leading to the second largest cause of illness and disability 
worldwide. It is also a major factor in female mortality, 
especially in low-resource settings. The consequences of 
unsafe sex are inextricably linked, resulting in an unmet 
need for products that provide simultaneous protection 
against unintended pregnancy and STIs, including HIV.
The Challenge 
Multipurpose prevention technologies are a unique and 
specialized subset of what regulatory agencies refer to 
as combination products. They often do not fit into the 
discrete categories—drug, device, or biologic—used by 
regulators to assess products. As such, MPTs face an 
uncertain regulatory environment that can serve as a 
major disincentive to investment and an impediment to 
advancing candidate products. 
The Opportunity
The current interest in scientific innovation provides 
an opportune moment to accelerate the development 
of combination products, including MPTs for SRH. 
Combination products represent cutting-edge science, 
employing new tools and techniques for product 
development. They also represent a promising area 
for health improvements and potentially greater user 
adherence. In some instances, combinations may lend 
themselves to more economical product development, 
lower costs, and potentially larger markets. 
The Response
The US Agency for International Development (USAID) 
is injecting new energy into efforts to develop and 
deliver MPTs by supporting complementary programs 
to foster creativity and strategic thinking on product 
development, innovative approaches to trial designs to 
test new products, and regulatory pathways for product 
development and licensure. The Population Council is 
playing a central role in this effort by spearheading work 
to clarify and inform regulatory pathways for MPTs. 
Main Project Activities: Facilitating 
Regulatory Approval for MPTs
Review existing guidance and its application to MPTs •	
for sexual and reproductive health
Convene dialogue with key thought leaders and •	
content area experts
Foster strategic engagement with regulators and •	
current/potential MPT product developers
Develop an MPT regulatory road map•	
GUIDING PRINCIPLES 
Focus on sexual and reproductive health
Solutions-oriented approach
Bridge reproductive health and HIV product 
development efforts
Glean insights from other products
Collaborate with and complement related 
initiatives
Working with the World Health Organization and 
other key stakeholders, the Council will stimulate 
thinking and promote problem-solving around MPT 
regulatory pathways with the goal of influencing and 
shaping regulatory approval processes for MPTs, and 
developing a road map of possible regulatory pathways as 
a foundation for their approval. The Council will engage 
key regulatory authorities such as the US Food and 
Drug Administration (FDA), European Medicines Agency 
(EMA), and drug regulatory authorities (DRAs) in select 
developing countries to review and understand existing 
guidelines and explore opportunities for stimulating new 
thinking and approaches. Thought leaders and experts 
from relevant fields—contraception, prevention of STIs 
including HIV, product development, clinical study design, 
and regulatory affairs—will also help shape regulatory 
processes for MPTs. 
Critical Path for MPTs 
Product developers must negotiate scientific and 
technical dimensions along the critical path from 
innovation to commercial product. Whether working 
with drugs, devices, or biologics—or some combination 
thereof—the pathway to product development 
encompasses scientific, technical, programmatic, and 
policy dimensions. As identified by the FDA, three 
crucial elements of the critical path are assessing safety, 
demonstrating medical and or public health utility, and 
industrialization. Equally important elements in delivering 
the product to the user include: 
Ensuring regulatory approval at global, country levels•	
Establishing licensing and distribution channels•	
Seeding and developing markets•	
Negotiating financing and procurement mechanisms•	
Generating demand among potential users, providers, •	
and policymakers
Developing service delivery guidelines and training•	
Creating an enabling policy environment •	
The Council’s approach to this complex and rapidly 
evolving arena is problem-solving and pragmatic. It 
draws on the Council’s decades of work to understand 
the needs and perspectives of diverse populations in 
resource-poor settings, and to develop and deliver 
programs and products to meet these needs. Identifying 
clear and efficient regulatory pathways for MPTs 
supports a key tenet of the Council’s work: ensuring that 
safe and effective technologies reach women and men 
most in need around the world. 
For more information, contact Martha Brady, Project Director, at 
mbrady@popcouncil.org.
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